Advertisement
UK markets close in 4 hours 1 minute
  • FTSE 100

    8,389.18
    -35.02 (-0.42%)
     
  • FTSE 250

    20,793.94
    -79.39 (-0.38%)
     
  • AIM

    808.62
    -1.32 (-0.16%)
     
  • GBP/EUR

    1.1702
    +0.0004 (+0.03%)
     
  • GBP/USD

    1.2716
    +0.0010 (+0.08%)
     
  • Bitcoin GBP

    56,005.60
    +3,145.58 (+5.95%)
     
  • CMC Crypto 200

    1,531.75
    +43.21 (+2.90%)
     
  • S&P 500

    5,308.13
    +4.86 (+0.09%)
     
  • DOW

    39,806.77
    -196.82 (-0.49%)
     
  • CRUDE OIL

    78.45
    -1.35 (-1.69%)
     
  • GOLD FUTURES

    2,421.80
    -16.70 (-0.68%)
     
  • NIKKEI 225

    38,946.93
    -122.75 (-0.31%)
     
  • HANG SENG

    19,220.62
    -415.60 (-2.12%)
     
  • DAX

    18,694.63
    -74.33 (-0.40%)
     
  • CAC 40

    8,117.70
    -78.26 (-0.95%)
     

Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Merus N.V.
Merus N.V.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 8:45 a.m. ET.

The webcast of the presentation will be contemporaneously available on the Investors page of the Company’s website. The archived presentation will also be available there for a limited time after the event.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, X and LinkedIn.

ADVERTISEMENT

Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.

CONTACT: Investor and Media Inquiries: Sherri Spear Merus N.V. VP Investor Relations and Corporate Communications 617-821-3246 s.spear@merus.nl Kathleen Farren Merus N.V. IR/Corp Comms 617-230-4165 k.farren@merus.nl